Völlegefühl, Blähungen und weicher oder drängender Stuhlgang sind die täglichen Begleiter eines SIBO. Es handelt sich um eine umstrittene Diagnose, die in der Regel nach einer verlangsamten Darmmotilität, früheren Operationen oder einer langfristigen Säureblockade auftritt. Die Identifizierung und Behandlung der zugrunde liegenden Ursache ist wirksamer als das wiederholte Durchlaufen von Behandlungszyklen.
Eine kurzzeitige low-FODMAP-Ernährung lindert die Symptome, während die Ursache abgeklärt wird. Rifaximin, ein darmzielgerichtetes Antibiotikum, ist das am besten untersuchte Medikament, wobei der Nutzen jedoch begrenzt ist.
Practice Ranking
Every practice we track for SIBO: What the Evidence Actually Supports, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
2 practices · 0 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | The Low-FODMAP Diet: What It Is, How the Three Phases Work, and What the Evidence Shows May ease overlapping IBS-type symptoms; direct SIBO evidence is thin. | Emerging | Self-Directed | Free to $ | Hard | Weeks | |
| 2 | Berberine: What It Does for Blood Sugar and Cholesterol Berberine-based herbal antimicrobial protocols cleared the breath test in 46% versus 34% on rifaximin in one open-label trial; comparable to the antibiotic on limited evidence. | Preliminary | Supplement | $ | Easy | Days to Weeks | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Small intestinal bacterial overgrowth, or SIBO, means too many bacteria in the small intestine, the long stretch of gut between stomach and colon that normally stays sparse. When bacteria build up there, they ferment food early, and a person feels that early fermentation as bloating, gas, abdominal discomfort, and stools that turn loose or urgent. SIBO names a physical phenomenon. It is also a contested diagnosis, because the breath test that diagnoses it agrees only loosely with what a direct sample of the small bowel shows.
The type of gas the test detects splits SIBO into four forms:
- Hydrogen-dominant SIBO leans toward bloating, gas, and loose or urgent stools. It overlaps most closely with IBS without constipation, the exact picture the drug trials studied.
- Intestinal methanogen overgrowth (IMO), the methane-producing form, tracks with constipation and hard stools, the reason methane-dominant SIBO was renamed.
- Hydrogen sulfide SIBO, a rotten-egg-gas pattern linked to diarrhea, is measured by recent breath testing that is still being validated.
- Recurrent SIBO means symptoms that clear and then return within weeks or months. It points to a cause that is still present.
What The Evidence Shows
The strongest evidence was measured in people with IBS. In culture-confirmed SIBO it is much thinner, so the trials show that symptoms ease, not that any treatment clears the overgrowth. A short low-FODMAP diet is the self-directed lever with the most support: it quiets symptoms over a few weeks, then a careful reintroduction. Rifaximin is the best-tested drug, and it helps only a minority beyond placebo. An elemental formula and herbal antimicrobials have weaker evidence and need a proper trial before anyone ranks them against the drug.
The breath test misses more than half of true cases. A positive result is a clue to SIBO, not a confirmation.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Digestion
Two-week rifaximin relieved IBS symptoms in 40.7% versus 31.7% on placebo
A two-week antibiotic course helped about 9 more people in 100 get relief of IBS symptoms and bloating than a dummy pill.
In two identically designed phase 3 placebo-controlled trials (TARGET 1 and TARGET 2), a two-week course of rifaximin 550 mg three times daily gave adequate relief of global IBS symptoms to 40.7% of patients versus 31.7% on placebo in the pooled analysis (P<0.001), and adequate relief of bloating to 40.2% versus 30.3%. The absolute difference is about 9 percentage points, an NNT of roughly 11. Measured in: Adults with IBS without constipation (about 1,260 across the two trials combined), followed for 10 weeks after treatment. These trials enrolled people by IBS symptoms and did not confirm SIBO by any test, so the result supports rifaximin for the diarrhea-leaning IBS picture, not proving it clears a bacterial overgrowth. The benefit is modest and the studies were funded by the drug maker. IBS trial populations skew female.
Who this may not transfer to:Pooled across two trials with a female-predominant IBS population; the effect is reported for both sexes together and was not broken out by sex in the primary report.
The study · 1
Pimentel et al., rifaximin therapy for patients with irritable bowel syndrome without constipation · N Engl J Med 2011;364(1):22-32
A repeat rifaximin course helped 38.1% versus 31.5%, mostly for pain
When symptoms came back, a second two-week antibiotic course helped a bit more than a dummy pill, mainly for pain.
In a phase 3 trial (TARGET 3), patients with diarrhea-predominant IBS who had responded to open-label rifaximin and then relapsed were randomized to repeat treatment. After the first repeat course, 38.1% responded versus 31.5% on placebo (P=0.03), with a significantly higher response for abdominal pain (50.6% versus 42.2%) but not for stool consistency. Measured in: 636 adults with diarrhea-predominant IBS who relapsed after responding to an initial open-label rifaximin course, randomized to repeat rifaximin (n=328) or placebo (n=308). The extra benefit over placebo is small, and this speaks to managing recurrence in IBS-D, not curing a confirmed overgrowth; it does not address why symptoms keep returning. Population skews female and SIBO was not confirmed by testing.
Who this may not transfer to:Female-predominant IBS-D population; results reported for both sexes together.
The study · 1
Lembo et al., repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome · Gastroenterology 2016;151(6):1113-1121
A low-FODMAP diet cut IBS symptom scores from 44.9 to 22.8
Eating a low-FODMAP diet roughly halved bloating, pain and gas scores compared with a normal diet in people with IBS.
In a randomized single-blind crossover feeding trial where almost all food was provided, people with IBS had lower overall gut symptom scores on a low-FODMAP diet (22.8 on a 0-100 scale) than on a typical Australian diet (44.9; P<0.001), with reductions in bloating, pain and passage of wind. Symptoms were unchanged in healthy controls. Measured in: 30 adults with IBS and 8 matched healthy controls, each spending 21 days on each diet with a washout between. A small, short crossover trial measuring symptoms, not bacterial overgrowth; it eases symptoms without treating any SIBO. Kept strict long term the diet narrows nutrition and can reduce beneficial gut bacteria, so it is intended as a short phase followed by reintroduction.
Who this may not transfer to:Small crossover with a female-predominant IBS group; results reported together, not by sex.
The study · 1
Halmos et al., a diet low in FODMAPs reduces symptoms of irritable bowel syndrome · Gastroenterology 2014;146(1):67-75
Proton pump inhibitor use carried 2.28 times the odds of SIBO
Long-term acid-blocking medication was linked to a higher chance of overgrowth, though the link depended heavily on how SIBO was diagnosed.
Across 11 studies (n=3,134), proton pump inhibitor use was associated with SIBO at a pooled odds ratio of 2.28 (95% CI 1.24 to 4.21). The association was strong when SIBO was diagnosed by duodenal or jejunal aspirate culture (OR 7.59) but absent when diagnosed by glucose breath test (OR 1.93, not significant), and funnel-plot analysis suggested possible publication bias. Measured in: Adult users of proton pump inhibitors versus non-users across 11 observational studies. This pools observational studies, so it shows association, not proof of cause, and the effect appears only with the most accurate diagnostic test. People on long-term acid suppression differ in age and comorbidity, and possible publication bias was noted. It is a reason to review a long-term acid-blocker with a prescriber, not to stop it abruptly.
Who this may not transfer to:Pooled mixed-sex populations; sex-specific risk was not separately reported.
The study · 1
Lo and Chan, proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis · Clin Gastroenterol Hepatol 2013;11(5):483-490
The 2020 ACG guideline recommends rifaximin on low-quality evidence
The main gastroenterology guideline does recommend antibiotics for SIBO, but rates the underlying evidence as weak.
The 2020 American College of Gastroenterology clinical guideline suggests using antibiotics such as rifaximin to treat symptomatic SIBO, but grades this as a conditional recommendation based on low-quality evidence, noting that most controlled data come from IBS populations, not culture-confirmed SIBO and that trials directly testing treatment in confirmed SIBO are small and few. Measured in: Systematic evidence review underpinning a professional-society clinical guideline for adults. A conditional recommendation on low-quality evidence means the treatment is reasonable but far from established for SIBO specifically; much of the support is borrowed from IBS trials, which is the gap that keeps this a contested area.
Who this may not transfer to:Guideline synthesis across mixed-sex evidence; no sex-specific recommendation was made.
The study · 1
Pimentel et al., ACG clinical guideline: small intestinal bacterial overgrowth · Am J Gastroenterol 2020;115(2):165-178
A 14-day elemental formula cleared the breath test in 80%
A two-week liquid formula diet cleared the abnormal breath test in about 4 of 5 people, and those people felt substantially better.
Among 93 people with IBS and an abnormal lactulose breath test, a 14-day exclusive elemental formula normalized the breath test in 74 (80%) by day 15, rising to 85% for those who continued to day 21. On later chart review, those who normalized reported a 66.4% improvement in bowel symptoms versus 11.9% in those who did not (P<0.001). Measured in: 93 adults with IBS and an abnormal lactulose breath test at a single motility clinic, open-label with no control group. This was an uncontrolled open-label series with no comparison group and symptom benefit judged from a chart review, so it cannot separate the diet from natural variation or expectation. The formula is unpalatable and expensive, and prolonged exclusive use needs supervision.
Who this may not transfer to:Single-clinic IBS series; sex distribution not the focus and results reported together.
The study · 1
Pimentel et al., a 14-day elemental diet is highly effective in normalizing the lactulose breath test · Dig Dis Sci 2004;49(1):73-77
Herbal antimicrobials cleared the breath test in 46% versus 34% on rifaximin
Herbal antimicrobials cleared the breath test about as often as the antibiotic, but the study was small and could not prove the herbs caused it.
In a retrospective single-center comparison of 104 patients with a positive lactulose breath test, four weeks of herbal antimicrobials cleared the follow-up test in 17 of 37 (46%) versus 23 of 67 (34%) on rifaximin (P=0.24). The adjusted odds ratio for a negative test with herbals versus rifaximin was 1.85 (95% CI 0.77 to 4.41), so the difference did not reach significance. Measured in: 104 adults with newly diagnosed SIBO by lactulose breath test at a tertiary gastroenterology practice, treated by patient and clinician choice, not randomization. What could explain it instead: Because treatment was chosen, not randomly assigned, the herbal and rifaximin groups may have differed in symptom severity, prior treatment and preferences; the analysis adjusted for age, sex, SIBO risk factors and IBS status but cannot remove such selection effects.. Retrospective and non-randomized, with a wide confidence interval that includes no real difference; the specific herbal products and doses varied. It is a signal that this is worth a proper trial, not evidence that herbals match or beat rifaximin.
Who this may not transfer to:Both sexes included and adjusted for in the analysis; effects reported for the combined group.
The study · 1
Chedid et al., herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth · Glob Adv Health Med 2014;3(3):16-24
Measurement And Diagnosis
The breath test found only 43.6% of cases with 83.6% specificity
Abnormal breath tests are commoner in IBS, but the test misses more than half of cases and does not on its own prove a bacterial overgrowth.
Pooling 11 case-control studies, an abnormal breath test was more common in IBS than in healthy controls (odds ratio 4.46, 95% CI 1.69 to 11.80), but the overall sensitivity was only 43.6% and specificity 83.6%, and the authors concluded the abnormal result does not by itself imply SIBO. A North American consensus later set standardized cutoffs precisely because interpretation had varied so widely. Measured in: Adults with IBS compared with healthy controls across 11 case-control breath-testing studies; consensus panel of expert gastroenterologists. Breath testing is an indirect measure and correlates imperfectly with direct small-bowel sampling, which is why SIBO remains a contested diagnosis; a positive test is best used alongside symptoms, not as a standalone confirmation.
Who this may not transfer to:A synthesis across mixed-sex study populations; sex was not a reported moderator.
The studies · 2
Shah et al., abnormal breath testing in IBS: a meta-analysis · Dig Dis Sci 2010;55(9):2441-2449
Rezaie et al., hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus · Am J Gastroenterol 2017;112(5):775-784
How It Works
The small intestine normally holds far fewer bacteria than the colon. Several defenses keep it sparse:
- stomach acid
- bile
- a working ileocecal valve
- the migrating motor complex, the wave of muscular activity that clears the small bowel between meals
SIBO develops when one of those defenses fails, and slow small-bowel motility is the common cause. It has several sources:
- the aftermath of gut surgery
- adhesions that kink the bowel
- nerve or muscle conditions that slow transit
- long-term acid suppression that removes the acid barrier
The same mechanism explains why SIBO returns. The overgrowth built up because a defense failed, and clearing bacteria leaves that failure in place, so the small bowel stays prone once treatment ends. Treating the current episode and then supporting motility beats repeating antibiotics over the long run.
Getting It Right
Match treatment to your symptoms, use the better-evidenced levers first, and spend the most effort on finding out why the overgrowth developed.
A positive test alone is not enough to act on, and a normal test does not rule SIBO out. Match any treatment to how you feel.
Rifaximin has the most trial support. Its effect is modest, and it relieves symptoms without clearing the overgrowth, so decide the course with a prescriber.
A few weeks of a low-FODMAP diet reliably quiets bloating, pain, and gas. Widen the diet back out afterward.
Keeping the small bowel active between meals, sometimes with a low-dose prokinetic, is used to lengthen the time before symptoms return. The evidence for that is thin, so treat it as a prescriber conversation.
Recurrence points to an underlying cause: slow motility, past abdominal surgery and adhesions, or long-term acid suppression. Addressing that cause does more over the long run than another round of antibiotics.
Go Deeper
SIBO overlaps three nearby conditions closely enough that they often belong in the same appointment:
- Irritable bowel syndrome: the overlapping diagnosis that the rifaximin and low-FODMAP trials studied.
- Chronic constipation: the picture the methane-associated form (IMO) overlaps.
- Acid reflux (GERD): where long-term acid-suppressing medication, one reviewable SIBO cause, usually comes from.
When to See Someone
Most of working with SIBO is steady and within your control, and one rule matters most: SIBO does not explain alarm features. When these are present, they point to a different or additional problem that needs its own assessment, not another round of SIBO treatment. These are the signs to get seen about:
- Vomiting blood, or black tarry stools, or visible blood in the stool, which needs prompt assessment for bleeding in the gut(seek urgent care)
- Fever with severe abdominal pain, or pain that is severe and fixed to one spot. Get same-day care.(seek urgent care)
- Unintended weight loss, drenching night sweats, or a lump you can feel in the abdomen. These point beyond overgrowth and need investigation.(seek urgent care)
- Iron-deficiency anemia, a low vitamin B12, or signs of poor absorption such as greasy, hard-to-flush stools, which can mean celiac disease, inflammatory bowel disease, or true malabsorption
- A new, persistent change in bowel habit after age 50, or a family history of bowel cancer, which is a reason for screening
- Symptoms that do not settle after a proper course of treatment, or that keep returning within weeks, which is the point to look harder for an underlying cause like slow motility or adhesions
SIBO is manageable, and the parts you control (the diet, the timing of treatment, and finding what is causing the recurrence) do much of the work. You can order your own breath testing through direct-to-consumer services if you want a number to start from.
Common Questions
Is a positive breath test enough to diagnose SIBO?
No. Across 11 studies the breath test picked up only 43.6% of cases, with a specificity of 83.6%. It misses more than half of them, and a positive result can appear without a true overgrowth. It correlates imperfectly with direct sampling of the small bowel, which is why SIBO is a contested diagnosis. A positive test is read alongside your symptoms, not treated as the answer on its own.
Does rifaximin cure SIBO?
It relieves symptoms for many people rather than curing an overgrowth. In the TARGET trials of people with IBS without constipation, a two-week rifaximin course gave adequate relief to 40.7% against 31.7% on placebo. That is about 9 more people helped in every 100. Those trials confirmed no SIBO by any test, so the benefit is best read as relief for the bloated, diarrhea-leaning picture. Symptoms often return, which points back to whatever let the overgrowth build up in the first place.
Should I follow a low-FODMAP diet for SIBO?
A short low-FODMAP phase is a reasonable way to quiet the symptoms. In a feeding trial it cut gut symptom scores from 44.9 to 22.8 on a 0-to-100 scale, with less bloating, pain, and gas. It eases symptoms and leaves any overgrowth in place. It is meant as a few weeks followed by careful reintroduction, since kept strict for months it narrows nutrition and thins out helpful gut bacteria.
Do herbal antimicrobials work as well as rifaximin?
The evidence cannot say yet. A single small retrospective study of 104 patients cleared the breath test in 46% on herbal antimicrobials against 34% on rifaximin, a difference well within chance. Because treatment was chosen rather than randomly assigned and the products varied, this is an early signal that the approach deserves a proper trial. It is not proof that herbs match the drug. Herbal antimicrobials also have a long record of traditional use, so the thin trial data marks missing research. If you try this route, products vary in quality, so look for third-party testing and clear sourcing.
Why does my SIBO keep coming back?
Because clearing the bacteria does nothing about the reason they built up. Overgrowth usually follows slow small-bowel motility, past surgery and adhesions, or long-term acid suppression, so the small bowel remains vulnerable to overgrowth after treatment ends. Supporting motility after a course, sometimes with a low-dose prokinetic, and finding the underlying cause does more for the long run than repeating antibiotics.
Should I stop my acid-blocker?
Not on your own. A meta-analysis linked long-term proton pump inhibitor use to SIBO at a pooled odds ratio of 2.28, strongest when SIBO was confirmed by small-bowel culture. That is a reason to review a long-term acid-blocker with the prescriber who started it and weigh why you are on it against the gut symptoms.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.